Robert Welte

Dikutip oleh

	Semua	Sejak 2020
Kutipan	2374	558
indeks-h	22	11
indeks-i10	32	13

160

120

1999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420257 12 30 34 57 58 59 104 128 125 104 149 87 111 102 92 88 118 100 107 107 103 126 126 104 86 11

Akses publik

Lihat semua

1 artikel

0 artikel

tersedia

tidak tersedia

Berdasarkan pada mandat pendanaan

Pengarang bersama

Maarten PostmaProfessor in PharmacoEonomicsEmail yang diverifikasi di rug.nl
Reiner LeidlProfessor of Health Economics and Health Care Management (ret.), LMU MunichEmail yang diverifikasi di lmu.de
Mirjam KretzschmarProfessor for Dynamics of Infectious DiseasesEmail yang diverifikasi di umcutrecht.nl
Prof. Dr. Hans-Helmut KönigUniversity Medical Center Hamburg-Eppendorf, Department of Health Economics and Health ServicesEmail yang diverifikasi di uke.de
Wolfgang GreinerProfessor für Gesundheitsökonomie und Gesundheitsmanagement, Universität BielefeldEmail yang diverifikasi di uni-bielefeld.de
Jan BakkerPontificia Universidad Católica de Chile, Department of Intensive CareEmail yang diverifikasi di erasmusmc.nl
T.L. FeenstraAssociate Professor of PharmacoEconomics, Groningen UniversityEmail yang diverifikasi di rug.nl
Philippe BeutelsProfessor at Vaccine & Infectious Disease Institute, University of Antwerp, BelgiumEmail yang diverifikasi di uantwerpen.be
John EdmundsProfessor of Infectious Disease Modelling, London School of Hygiene and Tropical MedicineEmail yang diverifikasi di lshtm.ac.uk
Caroline TrotterUniversity of CambridgeEmail yang diverifikasi di cam.ac.uk
Morre SAProfessor Host Pathogens Genomics, VU University medical centerEmail yang diverifikasi di vumc.nl
Stefan ScholzUniversity Hospital HalleEmail yang diverifikasi di uk-halle.de
J.-Matthias Graf von der SchulenburgLeibniz University HannoverEmail yang diverifikasi di ivbl.uni-hannover.de
Berit AndersenProfessor, Aarhus University, DenmarkEmail yang diverifikasi di rm.dk
Oliver DammSchool of Public Health, Bielefeld UniversityEmail yang diverifikasi di uni-bielefeld.de
Juergen WasemProfessor für Medizinmanagement, Universität Duisburg-EssenEmail yang diverifikasi di medman.uni-due.de
Boris V. SchmidQuantitative Veterinary Epidemiology, Wageningen University & Research, NetherlandsEmail yang diverifikasi di wur.nl
Florian KarlGlaxoSmithKlineEmail yang diverifikasi di gsk.com
Margarethe E. WackerHelmholtz Zentrum München GmbHEmail yang diverifikasi di helmholtz-muenchen.de
Ole MartenUniversität BielefeldEmail yang diverifikasi di uni-bielefeld.de

Ikuti

Robert Welte

Gilead Sciences

Email yang diverifikasi di gilead.com

economic evaluation health economics market access modelling quality of life


Judul Urutkan menurut kutipan Urutkan menurut tahun Urutkan menurut judul	Dikutip oleh Dikutip oleh	Tahun
A decision chart for assessing and improving the transferability of economic evaluation results between countries R Welte, T Feenstra, H Jager, R Leidl Pharmacoeconomics 22, 857-876, 2004	349	2004
Mortality, morbidity and costs attributable to smoking in Germany: update and a 10-year comparison S Neubauer, R Welte, A Beiche, HH Koenig, K Buesch, R Leidl Tobacco control 15 (6), 464-471, 2006	273	2006
Direct cost analysis of intensive care unit stay in four European countries: applying a standardized costing methodology SS Tan, J Bakker, ME Hoogendoorn, A Kapila, J Martin, A Pezzi, G Pittoni, ... Value in Health 15 (1), 81-86, 2012	203	2012
Health economics of infectious diseases R Welte, R Leidl, W Greiner, M Postma Modern Infectious Disease Epidemiology, 249-275, 2009	192*	2009
The costs of health damage and productivity losses attributable to cigarette smoking in Germany R Welte, HH König, R Leidl The European Journal of Public Health 10 (1), 31-38, 2000	161	2000
Comparative Model-based Analysis of Screening Programs for Chlamydia trachomatis Infections M Kretzschmar, R Welte, A Van den Hoek, MJ Postma American journal of epidemiology 153 (1), 90-101, 2001	160	2001
Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach R WELTE, M KRETZSCHMAR, R LEIDL, A VAN DEN HOEK, JC JAGER, ... Sexually transmitted diseases 27 (9), 518-529, 2000	135	2000
Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands JM Bos, H Rümke, R Welte, MJ Postma Clinical therapeutics 25 (10), 2614-2630, 2003	82	2003
Costs and effects of chlamydial screening: dynamic versus static modeling R Welte, M Postma, R Leidl, M Kretzschmar Sexually transmitted diseases 32 (8), 474-483, 2005	75	2005
Prediction of costs, effectiveness, and disease control of a population-based program using home sampling for diagnosis of urogenital Chlamydia trachomatis infections B Andersen, J Gundgaard, M Kretzschmar, J Olsen, R Welte, ... Sexually transmitted diseases 33 (7), 407-415, 2006	53	2006
Cost-utility of quadrivalent versus trivalent influenza vaccine in Germany, using an individual-based dynamic transmission model C Dolk, M Eichner, R Welte, A Anastassopoulou, LA Van Bellinghen, ... Pharmacoeconomics 34, 1299-1308, 2016	52	2016
Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making R Welte, G Van den Dobbelsteen, JM Bos, H de Melker, L van Alphen, ... Vaccine 23 (4), 470-479, 2004	52	2004
Übertragung der Ergebnisse ökonomischer Evaluationsstudien aus dem Ausland auf Deutschland: Probleme und Lösungsansätze. R Welte, R Leidl Ansätze und Methoden der ökonomischen Evaluation: eine internationale …, 1999	45*	1999
The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine R Welte, CL Trotter, WJ Edmunds, MJ Postma, P Beutels Pharmacoeconomics 23, 855-874, 2005	44	2005
Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review O Damm, J Witte, S Wetzka, C Prosser, S Braun, R Welte, W Greiner International Journal of Public Health 61, 847-860, 2016	40	2016
Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program JM Bos, HC Rümke, R Welte, MJ Postma, JC Jager Vaccine 20 (1-2), 202-207, 2001	38	2001
Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia trachomatis MJ Postma, R Welte, JAR Van Den Hoek, GJJ Van Doornum, ... Value in Health 4 (3), 266-275, 2001	31	2001
The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany S Scholz, F Koerber, K Meszaros, RM Fassbender, B Ultsch, RR Welte, ... Vaccine 37 (12), 1692-1701, 2019	29	2019
Cost impact of prospective HLA-B* 5701-screening prior to abacavir/lamivudine fixed dose combination use in Germany E Wolf, M Blankenburg, JR Bogner, W Becker, D Gorriahn, MC Mueller, ... European journal of medical research 15, 145-151, 2010	29	2010
Entwicklung eines Kriterienkataloges zur Beschreibung und Bewertung ökonomischer Evaluationsstudien in Deutschland U Siebert, C Behrend, N Mühlberger, J Wasem, W Greiner, ... Approaches and methods of economic evaluation in health care-an …, 1999	28	1999

Sistem tidak dapat melakukan operasi ini. Coba lagi nanti.

Artikel 1–20

Kutipan per tahun

Kutipan duplikat

Kutipan yang digabung

Tambahkan pengarang bersamaPengarang bersama

Ikuti

Dikutip oleh

Pengarang bersama